“We need to be holding their hand and whispering in their ear Neurontin for pain, Neurontin for monotherapy, Neurontin for bipolar, Neurontin for everything,” sales reps at Park-Davis, now Pfizer, were told in 1996 by senior executive John Ford. “I don’t want to hear that safety crap either.”
Eight years later, after thousands were harmed or killed from such off-label marketing — Neurontin could only be legally promoted for seizures and post-shingles nerve pain — a judgment against Pfizer awarded $430 million to the nation’s Attorneys General who earmarked $21 million for training products for prescribers to help prevent future Neurontins.
Read the rest of this article to see what health care professionals are doing to address the problem.

